Nitric Oxide Therapy in Adults with ARDS

Primary Recommendation

The American Thoracic Society recommends that inhaled nitric oxide should be restricted to salvage therapy only in adults with severe ARDS and life-threatening hypoxemia that has failed to respond to all other evidence-based interventions, as it consistently improves oxygenation but does not reduce mortality 1, 2
The Society of Critical Care Medicine suggests that inhaled nitric oxide should not be used routinely in adults with ARDS, as the evidence is clear that while nitric oxide improves physiological parameters, it has failed to demonstrate any mortality benefit in multiple randomized controlled trials 1, 2

The American College of Chest Physicians recommends that inhaled nitric oxide may be considered only after all of the following have been optimized and failed: lung-protective ventilation with tidal volumes 4-8 ml/kg predicted body weight and plateau pressures <30 cm H₂O 3, higher PEEP strategies (15 cm H₂O or greater) in moderate-severe ARDS 4, 5, 6, prone positioning for >12 hours daily in severe ARDS 3, and neuromuscular blockade (cisatracurium) when plateau pressures exceed 30-35 cm H₂O [7] [1, 2, 8]

The Society of Critical Care Medicine advises that nitric oxide should not be used before optimizing proven mortality-reducing interventions, such as lung-protective ventilation, prone positioning, or neuromuscular blockade 1, 2, 8, 7, 3

The American Thoracic Society provides a conditional recommendation for VV-ECMO in highly selected severe ARDS patients, though evidence certainty remains low, and suggests considering VV-ECMO at experienced centers rather than prolonged nitric oxide therapy 8

The American College of Chest Physicians recommends that nitric oxide improves oxygenation but not survival in adult ARDS, and should be reserved exclusively for salvage therapy in life-threatening hypoxemia after all evidence-based, mortality-reducing interventions have been exhausted 1, 2, 8

The Intensive Care Medicine expert consensus suggests that inhaled nitric oxide (5-10 ppm) may improve right ventricular function by reducing pulmonary vascular resistance without inducing systemic hypotension in patients with right ventricular failure, with moderate quality evidence 9
Inhaled nitric oxide (5-10 ppm) may be used to improve oxygenation in patients with severe ARDS, although its effectiveness in improving clinical outcomes is still uncertain, with low quality evidence 9

Typical dosing of inhaled nitric oxide as rescue therapy is 5-10 ppm, according to the Intensive Care Medicine expert consensus, with moderate quality evidence 9